Tavistock Life Sciences logo

Tavistock Life Sciences

North America, Florida, United States, Windermere

Description

Tavistock Life Sciences is a venture capital investment firm specialized in earl-stage investments.

Investor Profile

Tavistock Life Sciences has made 22 investments, with 0 in the past 12 months and 18% as lead.

Stage Focus

  • Series C (32%)
  • Post Ipo Equity (18%)
  • Series B (18%)
  • Pre Seed (9%)
  • Series Unknown (9%)
  • Private Equity (5%)
  • Series A (5%)
  • Series D (5%)

Country Focus

  • United States (77%)
  • Canada (14%)
  • United Kingdom (5%)
  • Australia (5%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Biopharma
  • Medical
  • Life Science
  • Pharmaceutical
  • Clinical Trials
  • Oncology
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Tavistock Life Sciences frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 6
OrbiMed
North America, New York, United States, New York
Co-Investments: 5
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 3
Aravis Ventures
Europe, Zurich, Switzerland, Zürich
Co-Investments: 3
5AM Ventures
North America, California, United States, Menlo Park
Co-Investments: 5
Versant Ventures
North America, California, United States, Menlo Park
Co-Investments: 4
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 3
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 3
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 3
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 3

What are some of recent deals done by Tavistock Life Sciences?

Kinotek

Portland, Maine, United States

Kinotek is a digital health platform revolutionizing musculoskeletal treatment and care.

EducationFitnessHealth CareInformation Technology
Pre SeedFeb 17, 2021
Amount Raised: $600,000
Nuvation Bio

New York, New York, United States

Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityFeb 11, 2021
Amount Raised: $502,000,000
AgeRate

Hamilton, Ontario, Canada

AgeRate develops a biotechnology platform that helps track aging in real time.

Health CareHealth DiagnosticsMedicalPersonal HealthWellness
Pre SeedSep 1, 2020
Amount Raised: $250,000
Mereo Biopharma

London, England, United Kingdom

Mereo is a new UK-based speciality biopharmaceutical company.

BiopharmaBiotechnologyHealth CareInnovation Management
Post Ipo EquityJun 4, 2020
Amount Raised: $70,000,000
Relay Therapeutics

Cambridge, Massachusetts, United States

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

BiotechnologyHealth CareTherapeutics
Series CDec 20, 2018
Amount Raised: $400,000,000
Atreca

San Carlos, California, United States

Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.

BiotechnologyHealth CareProduct ResearchTherapeutics
Series CSep 12, 2018
Amount Raised: $125,000,000
Inseego

San Diego, California, United States

Inseego specializes in providing enterprise SaaS solutions, IoT, and mobile solutions.

Asset ManagementFleet ManagementInternet of ThingsSaaSSoftwareTelecommunications
Post Ipo EquityAug 7, 2018
Amount Raised: $19,700,000
Avidity Biosciences

San Diego, California, United States

Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series BJan 5, 2017
Amount Raised: $16,000,000
G1 Therapeutics

Durham, North Carolina, United States

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.

BiotechnologyDeveloper PlatformMedicalOncologyTherapeutics
Series CMay 11, 2016
Amount Raised: $47,000,000
Syndax Pharmaceuticals

Waltham, Massachusetts, United States

Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.

BiotechnologyClinical TrialsHealth CarePharmaceutical
Series CAug 24, 2015
Amount Raised: $80,000,000